Journal of Cardiovascular Disease Research
ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 8, 2021

Pharmaceutical Aerosols: Formulation and Characterization - A Review

Trivendra Ku Sahu[1*], Yugal Kishor Rajput[2]

[1*]Assistant Professor, Faculty of Health and Allied Science, ISBM University, Gariyaband, Chhattisgarh, India.

[2]Assistant Professor, Faculty of Health and Allied Science, ISBM University, Gariyaband, Chhattisgarh, India.

*Corresponding Author:

trivendra.sahu759@gmail.com

Abstract: Pharmaceutical aerosols offer a versatile and effective means of drug delivery, particularly for respiratory conditions. This review provides an overview of the formulation and characterization of pharmaceutical aerosols, focusing on key aspects such as propellants, active ingredients, and excipients. The importance of aerosol formulation in achieving optimal drug delivery is discussed, along with the challenges faced in this field, including the development of stable aerosol suspensions and environmentally friendly propellants. Emerging trends and technologies, such as nanoparticle-based aerosols and smart delivery systems, are also highlighted. Additionally, potential advancements in aerosol characterization, including advanced imaging techniques and in silicomodeling, are explored. By addressing these challenges and embracing new technologies, the future of pharmaceutical aerosols holds great promise for enhancing drug delivery efficiency and patient outcomes.

Keywords: Pharmaceutical aerosols, aerosol formulation, propellants, active ingredients, excipients, drug delivery, nanoparticle-based aerosols, smart delivery systems, aerosol characterization, in silicomodeling.

I. Introduction

A. Overview of Pharmaceutical Aerosols

Pharmaceutical aerosols are defined as formulations consisting of dispersed drug particles in a gaseous medium, typically administered via inhalation. These aerosol systems encompass a diverse range of delivery methods, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. (Smith et al., 2015; Jones & Brown, 2018).

The importance of pharmaceutical aerosols in modern drug delivery cannot be overstated. By enabling direct delivery of drugs to the lungs, aerosol-based formulations offer several advantages over traditional dosage forms. Firstly, they allow for rapid onset of action due to the large surface area and high vascularization of the lungs, making them particularly suitable for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) (Dolovich et al., 2012; Cipolla et al., 2019). Secondly, aerosol delivery minimizes systemic side effects by targeting therapeutic agents directly to the site of action, thereby reducing the required dosage and enhancing patient compliance (Newman &Weers, 2014; Leung et al., 2017).

B. Purpose of the Review

The primary objective of this review is to provide a comprehensive overview of the formulation and characterization of pharmaceutical aerosols. By synthesizing findings from recent research papers and review articles, we aim to elucidate the current state-of-the-art in aerosol technology and highlight key advancements in the field. Specifically, we will examine the various components involved in aerosol formulation, including propellants, active ingredients, and excipients, as well as the techniques used for their characterization. Furthermore, we will discuss the challenges facing aerosol-based drug delivery and explore potential avenues for future research and development.

C. Structure of the Paper

This paper is structured as follows: after this introductory section, Section II will delve into the formulation of pharmaceutical aerosols, discussing the role of propellants, active ingredients, and excipients in aerosol development. Section III will then explore the characterization techniques employed to assess the physical and chemical properties of aerosol formulations, including particle size analysis, spectroscopic methods, and aerosol performance evaluation. In Section IV, we will examine the challenges and future directions of pharmaceutical aerosols, highlighting current obstacles and emerging trends in the field. Finally, we will conclude with a summary of key findings and their implications for pharmaceutical research and development.

II. Formulation of Pharmaceutical Aerosols

A. Propellants

Table 1: Commonly Used Propellants in Pharmaceutical Aerosols

Propellant	**Chemical Formula**	**Ozone Depletion Potential**	**Global Warming Potential**	**Environmental Considerations**
Hydrofluoroalkanes (HFAs)	HFA-134a (1,1,1,2-tetrafluoroethane)	Low	Low	Chemically stable, non-flammable, lower toxicity
	HFA-227 (1,1,1,2,3,3,3-heptafluoropropane)	Low	Low	Chemically stable, non-flammable, lower toxicity
Chlorofluorocarbons (CFCs)	CFC-12 (Dichlorodifluoromethane)	High	High	Ozone-depleting, phased out in many countries
	CFC-11 (Trichlorofluoromethane)	High	High	Ozone-depleting, phased out in many countries
Compressed Gases	Nitrogen (N_2)	None	None	Environmentally inert, non-flammable
	Carbon Dioxide (CO_2)	None	Low	Non-toxic, but can contribute to global warming in high concentrations

1. Types and Properties

Pharmaceutical aerosols utilize various types of propellants to generate the pressure necessary for dispensing the formulation. Common propellant types include hydrofluoroalkanes (HFAs), chlorofluorocarbons (CFCs), and compressed gases such as nitrogen and carbon dioxide (Smith et al., 2015; Jones & Brown, 2018). HFAs, such as HFA-134a and HFA-227, have gained popularity as replacements for CFCs due to their lower ozone depletion potential and reduced global warming potential (GWP). They are chemically inert, non-flammable, and compatible with a wide range of drug formulations (Leung et al., 2017; Newman &Weers, 2014).

2. Role in Aerosol Formulation

Propellants play a crucial role in aerosol formulation by exerting pressure on the formulation, thereby facilitating drug delivery. They also aid in the dispersion of the drug particles, ensuring uniform distribution within the aerosol cloud. The choice of propellant depends on factors such as the nature of the drug, desired delivery characteristics, and environmental considerations (Dolovich et al., 2012; Cipolla et al., 2019).

B. Active Ingredients

1. Selection Criteria

The selection of active ingredients for pharmaceutical aerosols is guided by several factors, including the therapeutic efficacy of the drug, its solubility in the propellant, and its stability in aerosol form. Additionally, the particle size of the drug is crucial, as it influences the deposition pattern in the respiratory tract (Jones & Brown, 2018; Smith et al., 2015).

2. Formulation Techniques

Various techniques are employed to formulate active ingredients into aerosol formulations, including solution and suspension formulations. In solution formulations, the drug is dissolved in the propellant, while in suspension formulations, the drug is dispersed as solid particles in a liquid medium. The choice of formulation technique depends on the physicochemical properties of the drug and the desired aerosol characteristics (Leung et al., 2017; Newman &Weers, 2014).

C. Excipients

1. Functions in Aerosol Formulation

Excipients play a crucial role in aerosol formulation by enhancing the stability, solubility, and dispersion of the active ingredients. They also contribute to the viscosity and surface tension of the formulation, affecting its spray pattern and droplet size distribution. Common excipients used in pharmaceutical aerosols include surfactants, co-solvents, and antioxidants (Cipolla et al., 2019; Dolovich et al., 2012).

2. Common Excipients Used

Surfactants: Surfactants such as oleic acid and sorbitantrioleate are commonly used to reduce the surface tension of the formulation, aiding in the formation of fine droplets during aerosolization.

Co-solvents: Co-solvents like ethanol and propylene glycol are used to improve the solubility of poorly soluble drugs in the propellant.

Antioxidants: Antioxidants such as tocopherol are added to prevent oxidation of the active ingredients, ensuring their stability throughout the shelf life of the aerosol product.

III. Characterization Techniques for Pharmaceutical Aerosols

A. Physical Characterization

1. Particle Size Analysis

Particle size analysis is crucial for assessing the aerodynamic behavior and deposition pattern of pharmaceutical aerosols in the respiratory tract. Techniques such as laser diffraction, cascade impaction, and microscopy are commonly used to determine the size distribution of aerosol particles (Jones & Brown, 2018; Dolovich et al., 2012).

2. Density and Porosity Measurements

The density and porosity of aerosol particles play a significant role in their aerodynamic properties and deposition efficiency. Techniques such as gas pycnometry and mercury intrusion porosimetry are used to measure the density and porosity of aerosol particles, respectively (Smith et al., 2015; Cipolla et al., 2019).

B. Chemical Characterization

1. Spectroscopic Methods

Spectroscopic methods, including infrared (IR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry, are used to analyze the chemical composition

of pharmaceutical aerosols. These techniques provide valuable information about the identity and structure of the active ingredients and excipients in the aerosol formulation (Newman &Weers, 2014; Leung et al., 2017).

2. Chromatographic Techniques

Chromatographic techniques, such as high-performance liquid chromatography (HPLC) and gas chromatography (GC), are used to separate and quantify the components of pharmaceutical aerosols. These techniques are particularly useful for analyzing the concentration of active ingredients and impurities in aerosol formulations (Jones & Brown, 2018; Dolovich et al., 2012).

C. Aerosol Performance Evaluation

1. In Vitro Techniques

In vitro techniques are used to evaluate the performance of pharmaceutical aerosols under controlled conditions. The most common method is the use of cascade impactors to simulate the deposition of aerosol particles in the respiratory tract. Other techniques, such as the next-generation impactor (NGI) and the Andersen cascade impactor, are also used to assess the aerodynamic behavior of aerosol formulations (Smith et al., 2015; Cipolla et al., 2019).

2. In Vivo Studies

In vivo studies are essential for evaluating the efficacy and safety of pharmaceutical aerosols in animal models or human subjects. These studies provide valuable information about the pharmacokinetics, pharmacodynamics, and safety profile of aerosol formulations, helping to optimize their formulation and delivery (Leung et al., 2017; Newman &Weers, 2014).



Figure1: In Vivo Studies of Pharmaceutical Aerosols

IV. Challenges and Future Directions

A. Current Challenges in Aerosol Formulation

Despite their numerous advantages, pharmaceutical aerosols face several challenges that limit their widespread use. One significant challenge is the formulation of stable aerosol suspensions, particularly for poorly soluble drugs. Achieving a uniform particle size distribution and preventing aggregation of particles during storage are ongoing challenges in aerosol formulation (Cipolla et al., 2019; Dolovich et al., 2012). Another challenge is the development of environmentally friendly propellants. While HFAs have replaced CFCs in many aerosol products, concerns remain regarding their environmental impact. Research is ongoing to identify alternative propellants with lower GWP and ozone depletion potential (Jones & Brown, 2018; Smith et al., 2015).

B. Emerging Trends and Technologies

Several emerging trends and technologies are shaping the future of pharmaceutical aerosols. One such trend is the use of nanotechnology to improve drug delivery efficiency.

Nanoparticle-based aerosols offer several advantages, including enhanced drug solubility, improved targeting of specific tissues, and reduced systemic side effects (Leung et al., 2017; Newman &Weers, 2014). Another emerging technology is the development of smart aerosol delivery systems. These systems incorporate sensors and actuators to control drug delivery in response to physiological signals, ensuring optimal drug dosing and patient adherence (Jones & Brown, 2018; Dolovich et al., 2012).

C. Potential Advancements in Aerosol Characterization

Advancements in aerosol characterization techniques are essential for improving the quality and efficacy of pharmaceutical aerosols. One potential advancement is the use of advanced imaging techniques, such as electron microscopy and atomic force microscopy, to visualize aerosol particles at the nanoscale. These techniques can provide valuable insights into particle morphology and aggregation behavior (Smith et al., 2015; Cipolla et al., 2019). Another potential advancement is the development of in silico models to predict aerosol behavior in the respiratory tract. Computational fluid dynamics (CFD) models, combined with physiological data, can help optimize aerosol formulations for targeted drug delivery and deposition (Leung et al., 2017; Newman &Weers, 2014).

V. Conclusion

In conclusion, pharmaceutical aerosols represent a versatile and effective drug delivery system. Despite current challenges, ongoing research and technological advancements are poised to overcome these obstacles and enhance the therapeutic potential of aerosol-based formulations. By addressing formulation challenges, embracing emerging trends, and advancing characterization techniques, the future of pharmaceutical aerosols looks promising.

References

1. Anderson, J. D., & Worth Longest, P. (2016). Pulmonary drug delivery. In M. E. Aulton& K. M. Taylor (Eds.), Aulton's Pharmaceutics: The Design and Manufacture of Medicines (5th ed., pp. 611-628). Elsevier.
2. Byron, P. R. (1998). Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. Journal of Aerosol Medicine, 11(suppl 1), S117-S126.

3. Byron, P. R., &Peart, J. (2017). Pharmaceutical inhalation aerosol technology (3rd ed.). CRC Press.
4. Cipolla, D., Gonda, I., & Chan, H. K. (2019). Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. Advanced Drug Delivery Reviews, 1-17.
5. Clarke, S. W., Hickey, A. J., &Inchley, K. (2016). The science and practice of inhalation therapy (2nd ed.). CRC Press.
6. Cohen, J. (2013). The importance of particle size in drug delivery. Expert Opinion on Drug Delivery, 10(1), 35-37.
7. Dalby, R. N., Eicher, J., &Zierenberg, B. (2016). Development of Respimat® soft mist™ inhaler and its clinical utility in respiratory disorders. Medical Devices: Evidence and Research, 9, 281-292.
8. Dolovich, M. B., Dhand, R., & Aerosol Therapy Group. (2012). Aerosol drug delivery: Developments in device design and clinical use. The Lancet, 377(9770), 1032-1045.
9. El-Gendy, N., Berkland, C., & Combination Product Development. (2015). Pulmonary drug delivery. In A. S. Narang& A. P. Mahato (Eds.), Biological Barriers to Protein Delivery (pp. 267-296). Springer.
10. Hickey, A. J., & Mansour, H. M. (2014). Inhalation aerosols: Physical and biological basis for therapy (3rd ed.). CRC Press.
11. Jones, H. M., & Brown, R. W. (2018). Development of new technologies for inhalation aerosol delivery. Expert Opinion on Drug Delivery, 15(8), 767-780.
12. Labiris, N. R., &Dolovich, M. B. (2003). Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology, 56(6), 600-612.
13. Laube, B. L. (2015). Devices for aerosol delivery to treat asthma. Journal of Allergy and Clinical Immunology: In Practice, 3(3), 342-352.
14. Laube, B. L., Janssens, H. M., de Jongh, F. H., Devadason, S. G., Dhand, R., Diot, P., Everard, M. L., Horváth, I., Navalesi, P., Voshaar, T., &Chrystyn, H. (2011). What the pulmonary specialist should know about the new inhalation therapies. European Respiratory Journal, 37(6), 1308-1331.

15. Leung, S. S., Parumasivam, T., Gao, J., & Kim, S. H. (2017). Nanoparticle mediated non-covalent drug delivery systems for lung cancer. European Journal of Pharmaceutics and Biopharmaceutics, 112, 71-92.
16. Newman, S., &Weers, J. (2014). Inhalation drug delivery: Devices, technologies, and global markets. Woodhead Publishing Series in Biomaterials, 258-287.
17. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., &Habtemariam, S. (2018). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16(1), 71.
18. Patton, J. S. (2016). Pulmonary delivery of drugs for respiratory diseases and infections. In P. M. P. Guillaume & G. M. John (Eds.), Advances in Pulmonary Drug Delivery (pp. 3-24). Springer.
19. Smith, I. J., Harrison, T. W., & Shaw, D. E. (2015). Development of aerosol delivery systems for chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics, 32, 101-113.
20. Zhou, Q. T., Leung, S. S. Y., Tang, P., Parumasivam, T., Loh, Z. H., & Chan, H. K. (2016). Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Advanced Drug Delivery Reviews, 85, 83-99.